

Accepted for publication 9 February 2011
 Allergy 2011; 66:1125–1127
 © 2011 John Wiley & Sons A/S
 DOI: 10.1111/j.1398-9995.2011.02575.x

References

1. Nicolaou N, Poorafshar M, Murray C, Simpson A, Winell H, Kerry G et al. Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics. *J Allergy Clin Immunol* 2010;**125**:191–197.
2. Holzhauser T, Wackermann O, Ballmer-Weber BK, Bindslev-Jensen C, Scibilia J, Perono-Garoffo L et al. Soybean (Glycine max) allergy in Europe: Gly m 5 (beta-conglycinin) and Gly m 6 (glycinin) are potential diagnostic markers for severe allergic reactions to soy. *J Allergy Clin Immunol* 2009;**123**:452–458.
3. Ballmer-Weber BK, Holzhauser T, Scibilia J, Mittag D, Zisa G, Ortolani C et al. Clinical characteristics of soybean allergy in Europe: a double-blind, placebo-controlled food challenge study. *J Allergy Clin Immunol* 2007;**119**:1489–1496.
4. van Zuuren EJ, Terreehorst I, Tupker RA, Hiemstra PS, Akkerdaas JH. Anaphylaxis after consuming soy products in patients with birch pollinosis. *Allergy* 2010;**65**:1348–1349.
5. Kosma P, Sjolander S, Landgren E, Borres MP, Hedlin G. Severe reactions after intake of soy drink in birch pollen allergic children sensitized to Gly m 4. *Acta Paediatr* 2011;**100**:305–307.
6. Brockow K, Ring J. Food anaphylaxis. *Anal Bioanal Chem* 2009;**395**:17–23.

Auto-reactive IgE responses to acidic ribosomal P₂ protein in systemic lupus erythematosus

C. Rhyner*, I. Daigle & R. Cramer

Keywords: autoantibodies; autoreactivity; IgE; ribosomal P₂ protein; systemic lupus erythematosus.

Systemic lupus erythematosus (SLE) is a prototype systemic autoimmune disease characterized by a loss of immune tolerance to self-antigens, uncontrolled production of autoantibodies, and

multiple clinical manifestations (1). Several immune disorders are involved in the pathogenesis of the disease, with a central role played by B cells ranging from antibody mediated and antibody independent actions to the presentation of autoantigens and the induction of CD4⁺ T helper cells of Th1, Th2, and Th17 subsets, as well as to the inhibition of regulatory T cells and the secretion of pro-inflammatory cytokines (1).

The autoantibodies found in SLE patients are directed against several cellular components, but mostly against nuclear components. The most prominent ones are disease-specific antibodies directed against double stranded DNA (dsDNA) found in a large proportion of SLE patients. They are specific for this disease and their presence correlates with the severity and activity of the disease. However, autoantibodies have been also found against other nuclear components, such as small nuclear ribonuclear proteins (Sm), nuclear ribonuclear proteins (nRNP), Ro and other cellular components (1), as well as to acidic ribosomal P proteins (2). P₂ proteins have also been described as minor allergens in fungal allergy where clinically relevant IgE antibodies have been found for Alt a 6, Cla h 4 and Asp f 8, the P₂ ribosomal proteins of *Alternaria alternata*, *Cladosporium herbarum* and *Aspergillus fumigatus* recognized by 8–22% of the patients sensitized to the corresponding moulds (3, 4). Interestingly, patients suffering from allergic bronchopulmonary aspergillosis (ABPA) or severe atopic eczema sensitized to Asp f 8 also show IgE antibodies against P₂ proteins of phylogenetically distant species, including human acidic ribosomal P₂ protein (4, 5). These observations are most likely explainable by cross-reactivity based on molecular mimicry deriving from the high sequence homology shared within the ribosomal P₂ protein family (Fig. 1A) (4). Here we investigated a possible role of IgE-mediated

Some SLE-patients show IgE-mediated autoreactivity to the P₂ self-antigen not explainable by cross-reactivity with allergens.

reactions to cross-reactive ribosomal P₂ proteins in SLE. We cloned, expressed and purified ribosomal P₂ proteins of *Homo sapiens*, *A. alternaria*, *A. fumigatus*, *C. herbarum*, and *Saccharomyces cerevisiae* and tested sera of SLE patients for the presence of autoantibodies of the IgG and IgE isotype. From a total of 90 SLE sera analyzed by ELISA, 67 (74%) showed specific IgG and 28 (31%) also specific IgE against human P₂ protein, whereas all IgE positive sera were also positive for IgG. Moreover, inhibition experiments with solid-phase coated human P₂ protein and homologous P₂ proteins in fluid phase demonstrated that they are capable to fully inhibit IgG (Fig. 1B) as well as IgE-binding (Fig. 1C) to the human self antigen, corroborating the specificity of the IgE-binding found in Western blot analysis (Fig. 1D). These results clearly show that i) sera of a subset of SLE patients contain IgE antibodies against the human P₂ self antigen, and ii) the IgG as well as the IgE-specific autoantibodies are fully cross-reactive with other members of the ribosomal P₂ protein family. However, because the SLE patients investigated are not sensitized to environmental allergens, it is unlikely that the IgE auto- and cross-reactivity to P₂ proteins derives from cross-reactivity resulting from molecular mimicry between environmental allergens and self-antigen. It is tempting to speculate that in this case the IgE derives from a genuine autoimmune reaction to human P₂ protein in SLE patients which are prone to switch B cells toward production of autoantibodies against self antigens. However, the clinical relevance of the observed cross-reactive IgE autoantibodies against P₂ proteins in SLE remains to be elucidated, as it is in most cases of IgE autoreactivity observed in allergic diseases (6).

We are grateful to Prof. A. Fontana for providing the sera of SLE patients. The authors declare no competing interest. Work supported by the Swiss National Science Foundation grant 320030_127618/1 and by the European Community's Seventh Framework Program [FP7-2007-2013] under grant agreement no. HEALTH-F2-2010-260338 "ALLFUN".




Figure 1 (A) Alignment of the recombinant Proteins: the height of the bar indicates the degree of conservation of an amino acid at a defined position. (B, C) Inhibition ELISA: Antigen was coated on plate (human ribosomal P2 protein) and serum pre-incubated with increasing amounts of soluble antigen was transferred to the plate. ELISA was developed with alkaline phosphatase conjugated anti human IgG (B) or anti human IgE (C) antibody, respectively. (D) Ribosomal P2 proteins were separated with SDS-PAGE, blotted on nitrocellulose membrane and incubated with serum from Systemic lupus erythematosus patients. Binding of specific IgE was detected using anti human IgE mAb TN-142 and developed using labelled secondary antibody.

*Department Molecular Allergology
 Swiss Institute of Allergy and Asthma Research
 (SIAF)
 Obere Strasse 22
 CH-7270 Davos
 Switzerland
 Tel.: +41 81 410 08 48
 Fax: +41 81 410 08 48
 E-mail: crhyner@siaf.uzh.ch

Accepted for publication 19 February 2011
 Allergy 2011; 66:1127–1129
 © 2011 John Wiley & Sons A/S
 DOI: 10.1111/j.1398-9995.2011.02581.x

References

1. Sanz I, Lee FE. B cells as therapeutic targets in SLE. *Nat Rev Rheumatol* 2010;**6**:326–337.
2. Rosen A, Casiola-Rosen L. Autoantigens in systemic autoimmunity: critical partner in pathogenesis. *J Intern Med* 2009;**265**:625–631.
3. Achatz G, Oberkofler H, Lechenauer E, Simon B, Unger A, Kandler D et al. Molecular cloning of major and minor allergens of *Alternaria alternata* and *Cladosporium herbarum*. *Mol Immunol* 1995;**32**:213–227.
4. Mayer C, Appenzeller U, Seelbach H, Achatz G, Oberkofler H, Breitenbach M et al. Humoral and cell-mediated autoimmune reactions to human acidic ribosomal P2 protein in individuals sensitized to *Aspergillus fumigatus* P2 protein. *J Exp Med* 1999;**189**:1507–1512.
5. Appenzeller U, Meyer C, Menz G, Blaser K, Cramer R. IgE-mediated reactions to autoantigens in allergic diseases. *Int Arch Allergy Immunol* 1999;**118**:193–196.
6. Zeller S, Glaser AG, Vilhelmsson M, Rhyner C, Cramer R. Immunoglobulin-E-mediated reactivity to self antigens: a controversial issue. *Int Arch Allergy Immunol* 2008;**145**: 87–93.

Affected person of a food hypersensitivity – claim of medical achievements in a Luxembourgian medical surgery

V. König*, N. Rösch, X. Miller & R. Mösges

Keywords: costs; food allergy; food hypersensitivity; Luxembourg; medical services.

According to international figures, the prevalence rate of food hypersensitivity varies between 3.24% and 34.9% (1, 2). A review of the literature reveals that no economic data and investigations into food hypersensitivity for the health-care system or the economic losses resulting from this disorder are available (3–5).

Within the scope of the research project MENSANA (Mobile Expert and Networking System for Systematical Analysis of Nutrition based Allergies), we evaluated the outpatient medical services provided to 46 patients with the clinical picture of food hypersensitivity from October 2008 up to September 2009 (Table 1). The data come from a Luxembourgian medical specialist in dermatology/venereology with further training in allergology. Either food allergy or nonallergic food hypersensitivity had to have been diagnosed or the suspicion of food hypersensitivity in the

broader sense had to have been investigated. Furthermore, patients were only included if they were 18 years and older at the time of examination. Overall, 46 patients were identified who fulfilled the designated criteria. Of these 46 people, 33 were women and 13 men. The average age was 43.15 years.

Besides the pure cost survey, the number and distribution of visits to the doctor's office were likewise interesting as a further parameter. The affected persons consulted the practice an average of 2.98 times during this 1-year period (mean 11.42 visits per month). A distortion of the distribution arises here for the month November in which the doctor's practice was closed for 2 weeks (four visits). The 46 patients made most doctor visits exactly in the months of April (19 visits) and July (18 visits) with their high pollen concentrations.

The diagnostic method most often used besides the personal consultation or anamnesis is the radioallergosorbent test. This test was not conducted in only three of the 46 patients; four patients received even two tests. In the process, the blood of the patients was examined

This is an analysis of costs to diagnose and treat patients with food hypersensitivity.

Table 1 Total medical services and expense distribution

(n = 46)	Total	Per patient
Practice-related medical services	368	8
Costs	6031.06€	131.11€
Diagnostic methods	188	4.09
Personal consultation/anamnesis	104	2.26
Prick test	22	0.48
Epicutaneous test	15	0.33
RAST	47	1.02
Diamine oxidase	16	0.35
IgE total	40	0.87
Food allergens	287	6.24
Prescribed medications	206	4.48
Costs	5195.92€	112.95€
Absorption of Costs (CNS)	3992.14€	86.79€
Patients' contribution	1203.78€	26.17€
Medical services (incl. laboratory tests) and prescribed drugs	15057.64€	327.34€
Median		323.94€
SD		111.43€
Variance		12416.19€
Minimum		93.17€
Maximum		575.79€
Confidence interval (95%)		[294.25€; 360.43€]